Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

40 results about "Fibroblast growth factor receptor 2" patented technology

Fibroblast growth factor receptor 2 (FGFR2) also known as CD332 (cluster of differentiation 332) is a protein that in humans is encoded by the FGFR2 gene residing on chromosome 10. FGFR2 is a receptor for fibroblast growth factor.

Antitumor agent for undifferentiated gastric cancer

ActiveUS20090264464A1High therapeutic effectBiocideOrganic chemistryKinase activityUndifferentiated Gastric Carcinoma
The present invention relates to a therapeutic agent represented by the General formula (I), or a pharmacologically acceptable salt thereof, or a solvate of the compound or the salt thereof:The therapeutic agent comprises a substance having the activity of inhibiting kinase activity of fibroblast growth factor receptor 2 (“FGFR2”). The therapeutic agent can be used for treating undifferentiated gastric cancer, and can also be used to treat organisms comprising a cell overexpressing FGFR2 or a cell expressing mutant FGFR2, or both. The present invention further relates to a pharmaceutical composition comprising an FGFR2 inhibitory and methods of treatment therewith. The present invention also relates to a method for predicting the effect of an FGFR2 inhibitory substance on a patient.
Owner:EISIA R&D MANAGEMENT CO LTD

Serum-free medium for culturing placenta mesenchymal stem cells

The invention discloses a serum-free medium for culturing placenta mesenchymal stem cells. The serum-free medium takes a DMEM (Dulbecco Modified Eagle Medium) culture solution as a basis and also contains a fibroblast growth factor receptor 2, growth hormone, insulin, transferrin, glutathione, BMP-4, L-glutamine, sodium pyruvate, non-essential amino acids and beta-mercaptoethanol. According to various serum-free media provided by the invention, growth and proliferation of the placenta mesenchymal stem cells in a serum-free medium system can be effectively promoted, the placenta mesenchymal stem cells have higher growth and proliferation rate in the serum-free medium system compared with a serum cell culture medium, the characteristics of the stem cells are preserved, the serum-free medium has multiple differential potentials, and the stem cells can be directionally induced into fat cells and osteoblasts.
Owner:章毅 +10

Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said method

The present invention relates generally to methods of in vitro diagnostics, in particular the use of a compound selected from the group consisting of fibroblast growth factor 23 (FGF23), inorganic phosphorus (P), the product of inorganic phosphorus and total calcium (P×tCa), osteopontin (OPN) and parathyroid hormone (PTH) as biomarker. Said biomarkers can be used to monitor the modulation of fibroblast growth factor receptor (FGFR) kinase activity, in particular its inhibition, and / or the occurrence of secondary effects of FGFR inhibition. The invention further provides methods and kits relating to these uses.
Owner:NOVARTIS AG

Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof

The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.
Owner:FIBRON

Monoclonal antibodies to fibroblast growth factor receptor 2

The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Owner:GALAXY BIOTECH LLC

Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2

The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and / or 253.
Owner:FIVE PRIME THERAPEUTICS

Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof

The present invention is related to antibodies with binding affinity to fibroblast growth factor receptor 2 (FGFR2) optionally with binding affinity to other FGF receptors, which block both ligand-dependent and constitutive ligand independent receptor activation. Specifically, the present invention relates to antibodies with high affinity to more than one FGF receptor subtype, and fragments thereof, useful in treating disorders including cell proliferative diseases.
Owner:FIBRON

Antisense modulation of fibroblast growth factor receptor 2 expression

Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 2. Methods of using these compounds for modulation of fibroblast growth factor receptor 2 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 2 are provided.
Owner:IONIS PHARMA INC

Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof

The invention features soluble fibroblast growth factor receptor 3 (sFGFR3) polypeptides. The invention also features methods of using sFGFR3 polypeptides to treat skeletal growth retardation disorders, such as achondroplasia.
Owner:PFIZER INC +2

Use of fgfr1 extra cellular domain proteins to treat cancers characterized by ligand-dependent activating mutations in fgfr2

The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and / or 253.
Owner:FIVE PRIME THERAPEUTICS

Fibroblast growth factor receptor 2-specific peptide reagents and methods

The present disclosure relates to Fibroblast Growth Factor Receptor 2-specific peptide reagents, methods for detecting epithelial-derived cancer cells such as esophageal, colorectal, gastric, pancreatic or breast carcinoma cells using the peptide reagents, and methods for targeting such cells using the peptide reagents.
Owner:RGT UNIV OF MICHIGAN

Polypeptide capable of regulating activity of FGFR2 (Fibroblast Growth Factor Receptor 2)

The invention discloses a polypeptide capable of regulating the activity of FGFR2 (Fibroblast Growth Factor Receptor 2). The amino acid sequence of the polypeptide is Asn-Leu-Gly-Gln-Glu-Leu-Ala-Phe-Arg-Val-Pro-Asn. The polypeptide disclosed by the invention can be specifically combined with the FGFR2, plays an obviously regulating role on the activity of the FGFR2, can outstanding inhibit the activity of p-ERK (Phospho-Extracellular Signal-Regulated Kinase) contained in the main downstream signal channel MAPK (Mitogen Activated Protein Kinase) of the FGFR2, has the advantages of low molecular weight, easiness for preparation, controllability in quality, low immunogenicity and the like and has good potential application value in the field of medicines.
Owner:THE THIRD AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIV OF PLA

Antisense modulation of fibroblast growth factor receptor 3 expression

Antisense compounds, compositions and methods are provided for modulating the expression of fibroblast growth factor receptor 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding fibroblast growth factor receptor 3. Methods of using these compounds for modulation of fibroblast growth factor receptor 3 expression and for treatment of diseases associated with expression of fibroblast growth factor receptor 3 are provided.
Owner:IONIS PHARMA INC

Novel splice variant of FGFR3 (Fibroblast Growth Factor Receptor 3) in liver carcinoma tissue and application thereof

The invention discloses a novel splice variant of FGFR3 (Fibroblast Growth Factor Receptor 3) in liver carcinoma tissue and application thereof. The novel splice variant is FGFR3 delta7-9, and the gene sequence of FGFR3 delta7-9 is CGCTGGACGTGCTGGCCGAGGAGGAGCTGG. According to the novel splice variant FGFR3 delta7-9, proliferation and transfer of hepatoma carcinoma cells are promoted, the growth of subcutaneous hepatoma carcinoma cell transplantation tumor of a naked mouse is further promoted; besides, the experimental result shows that FGFR3 delta7-9 can serve as the diagnostic marker of liver cancer, therefore whether the splice variant FGFR3 delta7-9 exists in the liver carcinoma tissues of patients has higher guiding significance on the judgment of prognosis in liver cancer.
Owner:RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Glypican-1 in human breast cancer

Glycosylphosphatidylinositol-(GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer—both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts—whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues. Temporary or permanent transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. Glypican can be used to detect the carcinoma in vitro and therapeutics that either bind to (e.g., antibodies or drugs), remove (e.g., enzymes) or prevent the expression (e.g., antisense constructs) of surface of the extracellular domain of glypican-1 are effective in retarding the growth of glypican-responsive carcinomas.
Owner:RGT UNIV OF CALIFORNIA

Detection reagent for detecting anti-hepatoma natural antibodies, reagent kit and method

The invention relates to an antigen polypeptide detection reagent used for detecting VEGFR1 (vascular endothelial growth factor receptor 1) and FGFR2 (fibroblast growth factor receptor 2) natural antibodies, a reagent kit containing the detection reagent, a method for detecting the concentrations of the VEGFR1 and FGFR2 natural antibodies in a sample by use of the detection reagent or the reagentkit as well as an application of the detection reagent or the reagent kit in detection of the VEGFR1 and FGFR2 natural antibodies in the sample. Two linear antigen polypeptides completely complementary with the VEGFR1 and FGFR2 natural antibodies are used for qualitative and quantitative detection of the anti-hepatoma natural antibodies in the sample and the detection reagent and the reagent kit can be used for distinguishing blood plasma containing rich VEGFR1 and FGFR2 natural antibodies and blood plasma without VEGFR1 and FGFR2 natural antibodies.
Owner:QINGDAO HAILANSHEN BIOTECH

Method of identification of cells that show sensitivity to modulation of signaling mediated by a fibroblast growth factor receptor or a variant thereof

The invention is based on the finding that cells that show (especially tyrosine) phosphorylation of FGF-R substrate 2 (FRS-2), in contrast to cells that lack such phosphorylation, allow a prediction that treatment with a modulator, especially an inhibitor, of Fibroblast Growth Factor-Receptor signaling will be successful in cells e.g. from biological samples from patients that show such phosphorylation. Therefore, the phosphorylation of FRS-2 can serve as a biomarker for the possibility of successful treatment. The invention relates to various methods, uses, kits and reagents useful in applying this biomarker.
Owner:GRAUS PORTA DIANA +2

Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof

Antibody molecules that specifically bind to one or more isoforms expressed and / or associated with oncogenic phenotypes in a hyperproliferative cell (e.g., a cancerous or tumor cell) are disclosed. The isoform-binding antibody molecules can be used to treat, prevent and / or diagnose cancerous conditions and / or disorders. Methods of using the isoform-binding molecules to selectively detect oncogenic isoforms, to reduce the activity and / or induce the killing of a hyperproliferative cell expressing an oncogenic isoform in vitro, ex vivo or in vivo are also disclosed. Diagnostic and / or screening methods and kits for evaluating the function or expression of an oncogenic isoform are also disclosed.
Owner:艾托生物有限公司

Glypican-1 in human breast cancer

InactiveUS7108986B2Growth stimulatory effectDecrease glypicanSamplingPeptide/protein ingredientsInsulin-like growth factorHigh level expression
Glycosylphosphatidylinositol-(GPI-) anchored HSPG glypican-1 is strongly expressed in human breast and pancreatic cancer—both by the cancer cells and in the case of pancreatic cancer the adjacent fibroblasts—whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors: fibroblast growth factor-2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). Treatment of MDA-MB-231 and MDA-MB-468 breast cancer cells with PI-PLC abrogates the mitogenic response to two heparin-binding growth factors, heparin-binding epidermal growth factor-like growth factor (HB-EGF) and fibroblast growth factor-2 (FGF-2). Syndecan-1 is also expressed at high levels in breast cancer tissues as well as breast cancer cells by comparison with breast normal tissues. Temporary or permanent transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. Glypican can be used to detect the carcinoma in vitro and therapeutics that either bind to (e.g., antibodies or drugs), remove (e.g., enzymes) or prevent the expression (e.g., antisense constructs) of surface of the extracellular domain of glypican-1 are effective in retarding the growth of glypican-responsive carcinomas.
Owner:RGT UNIV OF CALIFORNIA

SRM/MRM Assay for the Fibroblast Growth Factor Receptor 2 (FGFR2) protein

Methods are provided for quantifying the fibroblast growth factor receptor 2 protein (FGFR2) directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) / Multiple Reaction Monitoring (MRM) mass spectrometry. The biological sample may be selected from tissues and cells treated with formaldehyde containing agents / fixatives including formalin-fixed tissue / cells, formalin-fixed / paraffin embedded (FFPE) tissue / cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells. A protein sample is prepared from the biological sample and the FGFR2 protein is quantitated in the sample using the method of SRM / MRM mass spectrometry by quantitating in the protein sample at least one fragment peptide derived from FGFR2.
Owner:EXPRESSION PATHOLOGY

Nucleic acid composition, kit and detection method for detecting fusion mutation of human FGFR2 (fibroblast growth factor receptor 2) gene

The invention discloses a nucleic acid composition, kit and detection method for detecting fusion mutation of a human FGFR2 (fibroblast growth factor receptor 2) gene. The nucleic acid composition comprises primers and probes designed for 18 fusion mutation types of the FGFR2 gene. The kit comprises the nucleic acid composition, and also comprises DNA polymerase, a PCR buffer solution, dNTPs and cations. The invention also provides a method for detecting fusion mutation of the FGFR2 gene. The method comprises the following steps: firstly, extracting RNA of a detection sample, carrying out reverse transcription to obtain cDNA, carrying out real-time fluorescent PCR reaction by using the kit with the cDNA as a template, and finally judging the negative and positive properties of the detection sample according to a Ct value. The kit can be used for simultaneously and specifically detecting 18 fusion mutations of the FGFR2 gene, is wide in mutation site coverage range, reduces the detection times, and has the advantages of high sensitivity, good repeatability, simplicity and convenience in operation, high detection speed, easiness in result interpretation and the like.
Owner:江苏申基生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products